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Abstract 
Background: Angiosarcoma is a rare subgroup of soft tissue sarcomas associated with poor prognosis, but paclitaxel 
has been shown to be active in pretreated metastatic disease. We investigated the efficacy and safety of weekly pacli‑
taxel as first‑line chemotherapy in adult patients with metastatic angiosarcoma.
Methods: A retrospective study using the Samsung Medical Center (Seoul, Korea) cancer chemotherapy registry 
was performed on 21 consecutive patients with angiosarcoma who were treated with weekly paclitaxel as first‑line 
therapy for metastatic disease between Oct. 2008 and Dec. 2014. We excluded patients who were enrolled in clini‑
cal trials to ensure the results would reflect the real‑world outcomes obtained in a daily clinical setting. Endpoints 
included efficacy in terms of response rate, progression‑free survival (PFS), overall survival (OS) and safety.
Results: Among 21 patients, 15 (71 %) were male and the median age was 53 years (range, 24–76). Primary sites of 
angiosarcoma were the visceral organs (33 %), scalp (29 %) and heart (23 %). The median number of metastatic sites 
was two (range, 1–5) with the lungs being the most frequently involved site. Weekly paclitaxel was generally well 
tolerated: the major hematologic toxicity was grade 1/2 anemia (24 %). Among non‑hematologic toxicities, grade 1/2 
peripheral neuropathy was most commonly observed (67 %). Objective response was observed in 11 (52 %) patients 
(4 complete and 7 partial responses). With a median follow‑up of 21 months, the estimated median PFS and OS were 
5.7 months (95 % CI 5.1–6.3) and 18.6 months (95 % CI 9.9–27.3), respectively.
Conclusions: In this retrospective study, first‑line chemotherapy with weekly paclitaxel demonstrated clinically 
relevant efficacy and tolerability in unselected Korean patients with metastatic angiosarcoma. It is encouraging that 
response rate and PFS for Korean patients were similar to those reported in Western reports.
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Background
Angiosarcoma is a rare (2 %) subgroup of soft tissue sar-
coma (STS) derived from endothelial cell lineage associ-
ated with aggressive behavior and poor prognosis [1, 2]. 
When localized, complete surgical resection of tumors 
and adjuvant radiotherapy is the treatment of choice. 
However, surgery is often challenging, as some cases of 
angiosarcoma occur in the face or in other vital organs 
such as the heart and great vessels. According to a previ-
ous report [3], one-third of patients with localized angio-
sarcoma did not receive surgery because of its location 
and/or rapid progression. In general, the prognosis of 
angiosarcoma remains poor, even treatment with aggres-
sive surgical resection is associated with a 5  year sur-
vival rate of 60 %, with median survival of 7 months [3]. 
Similar to other STS subtypes [4], conventional cytotoxic 
chemotherapy has shown limited success in angiosar-
coma [5]. More than a few decades’ worth of clinical trials 
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have indicated that cytotoxic chemotherapy with anthra-
cyclines and/or ifosfamide is the standard for first-line 
treatment [6]. Unfortunately, with the exception of pazo-
panib in the second-line setting [7], clinical trials involv-
ing novel agents have had little success in the treatment 
of angiosarcoma. Nevertheless, it is of note that some ret-
rospective studies have demonstrated that paclitaxel has 
favorable efficacy in angiosarcoma with improved sur-
vival [6, 8–10]. In a retrospective study written by Penel 
et al. [6], weekly paclitaxel given as first-line regimen was 
an independent parameter for improved survival. Cuta-
neous angiosarcoma responded more favorably to weekly 
paclitaxel than to doxorubicin [10].
Current guidelines recommend the use of paclitaxel, 
docetaxel, or all available systemic therapy options for 
STS as a first-line treatment for angiosarcoma [11]. 
Based on the results presented in the ANGIOTAX 
phase II study [12], as well as other retrospective studies 
described above, our institutionalstandard for first-line 
treatment of metastatic angiosarcoma has been weekly 
paclitaxel since 2008.
The choice of a first-line regimen for an individual 
patient may be important, since not all patients are eli-
gible for salvage treatment, which obviously provides 
a rationale to first administer the most effective treat-
ment. Factors to be considered include the experiences 
of the treating oncologists, potential toxicity, especially 
for those with symptoms or with decreased performance 
status, as well as the activity of chemotherapeutic agents. 
In prospective clinical trials including the ANGIOTAX 
[12], patients were selected on the basis of a fairly pre-
served performance status and normal organ function. 
Angiosarcoma is a highly aggressive disease that often 
exhibits rapid progression and clinical decline; therefore, 
the clinical trial population might not be indicative of 
all patients seen in daily oncology practice. In an effort 
to generate real-world data in Korean metastatic angio-
sarcoma patients, we conducted a retrospective review of 
a prospectively collected cancer chemotherapy registry. 
Although this study is limited by the retrospective nature 
of the analysis, the present evaluation was also done with 
the intent to develop improved therapeutic strategies for 
angiosarcoma patients with metastatic disease and sup-
port further prospective studies to better define the full 
therapeutic potential of paclitaxel.
Patients and methods
Institutional Review Boards approval was obtained from 
Samsung Medical Center (SMC; Seoul, Korea). Written 
informed consent was given by all patients prior to start-
ing chemotherapy, according to institutional standards. 
We retrospectively collected and reviewed the data of 
21 adult patients with histologically-proven, metastatic 
angiosarcoma who were consecutively treated with 
weekly paclitaxel as first-line chemotherapy between 
Oct. 2008 and Dec. 2014. We excluded patients who were 
enrolled in clinical trials to ensure the study population 
reflected our daily clinical practice, and the choice of 
weekly paclitaxel was solely at the discretion of the treat-
ing oncologists. Other exclusion criteria for patient selec-
tion were as follows: (1) prior chemotherapy or targeted 
therapy for advanced or metastatic disease, (2) mixed 
histology with other STS subtypes, (3) another malig-
nancy within 5  years, and (4) patients with inappropri-
ate laboratory findings or severe comorbid illness for 
standard 80 mg/m2 weekly doses of paclitaxel. If adjuvant 
chemotherapy had been completed more than 6 months 
before the start of weekly paclitaxel, the patient could be 
included onto the study.
In all patients, chemotherapy was administered on an 
outpatient basis. Each chemotherapy cycle consisted of 
intravenous infusion of paclitaxel 80 mg/m2 over 1 h on 
days 1, 8 and 15. Premedications included dexametha-
sone 20  mg, chlorpheniramine 4  mg and ranitidine 
50  mg intravenously. Other supportive care including 
the administration of anti-emetics, blood products, and 
the use of analgesics was given if judged appropriately 
by the treating physicians. Before initiating the first 
dose of chemotherapy, patients had a complete history 
taken, and underwent complete blood counts and serum 
chemistries, chest x-rays, and computed tomography 
scans of all involved sites. Patients were seen every 
4  weeks as chemotherapy was repeated every 4  weeks. 
Therapy was continued until objective disease progres-
sion per Response Criteria in Solid Tumors (RECIST) 
[13], unacceptable toxicity or deterioration of clinical 
status, or patient refusal. Dose adjustments at the start 
of a new cycle were based on the worst toxicity observed 
during the previous cycle. For hematologic toxic-
ity, subsequent cycles were delayed for up to 2  weeks 
if grade >2 toxicities appeared. The doses of paclitaxel 
were reduced if grade 4 myelosuppression or febrile 
neutropenia was present, and if myelosuppression or 
febrile neutropenia persisted an additional reduction of 
doses was required. If there was a third such episode, 
chemotherapy was discontinued. In case of Grade ≥2 
non-hematologic toxicity, treatment was delayed until 
recovery but not for more than 2  weeks. Doses were 
reduced in the case of severe non-hematologic toxic-
ity that was not controllable with usual measures, and 
treatment was discontinued if the patient experienced 
a significant hypersensitivity reaction or unacceptable 
toxicity (e.g., Grade 4 stomatitis or diarrhea, Grade ≥3 
peripheral neuropathy, severe and persistent skin/nail 
changes). Chemotherapy administration could be omit-
ted if one of the following toxicities was noted on day 
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8 or day 15: Grade ≥2 hematologic or non-hematologic 
toxicities, fever ≥38  °C, diarrhea of any grade, or a 
decrease in performance status.
Baseline characteristics and outcome data were col-
lected using a uniform case report form. Clinical and 
laboratory parameters collected at the time of starting 
chemotherapy included age, gender, Eastern Coopera-
tive Oncology Group (ECOG) performance status, his-
tological grade according to Fédération Nationale des 
Centres de Lutte Contre le Cancer (FNCLCC), primary 
site, previous surgery and/or radiotherapy, blood counts 
and chemistries, time between diagnosis and paclitaxel 
therapy, and sites of metastases. Responses were evalu-
ated every two cycles by chest and abdominopelvic com-
puted tomography or by the same tests that were used to 
stage initial tumors. Adverse events were collected and 
graded according to the National Cancer Institute crite-
ria. To determine the causes of death, as well as therapy 
discontinuation, a structured medical record review was 
performed.
The primary end point was the response rate (RR). Sec-
ondary end points included progression-free survival 
(PFS), overall survival (OS), and toxicity profile. PFS and 
OS were calculated using the Kaplan–Meier method. To 
examine the impact of baseline parameters collected on 
PFS and OS, Cox proportional hazard model was used. 
Laboratory parameters and age were initially recorded as 
continuous variables, and evaluated as both continuous 
and categorical variables. The potential presence of inter-
action effects between baseline parameters was tested 
by defining product terms for the respective factors in 
a regression model. All P values were two-sided, with 
P  <  0.05 indicating statistical significance. All analyses 
were performed using the R for Windows v2.11.1 soft-
ware (R Core Team, Vienna, Austria; http://www.Rpro-
ject.org).
Results
The SMC cancer chemotherapy registry identified 21 
eligible patients who were treated with first-line weekly 
paclitaxel for metastatic angiosarcoma. Patient charac-
teristics are given in Table 1. As shown, men constituted 
71  % of the patients and the median age was 53  years 
(range 24–76). Four (19 %) patients had been treated with 
adjuvant chemotherapy, involving doxorubicin/ifosfa-
mide (n = 2) and etoposide/ifosfamide/cisplatin (n = 2). 
Primary sites of angiosarcoma were visceral organs 
(33 %), scalp (29 %) and heart (23 %). Approximately 67 % 
of the patients had two or more metastatic disease sites, 
mostly involving the lungs, lymph nodes and bone. At the 
time of data collection, with a median follow-up duration 
of 21  months, 20 patients showed disease progression 
and 14 patients died.
All 21 patients were evaluable for efficacy and safety. A 
total of 102 4-week chemotherapy cycles were adminis-
tered (median 5, range 1–9). All but one patient received 
at least two cycles of weekly paclitaxel chemotherapy. 
The most common reason for chemotherapy discon-
tinuation was disease progression. Overall, first-line 
weekly paclitaxel was generally well tolerated, with ane-
mia and peripheral neuropathy being the most com-
monly observed toxicities (Table 2). One patient died of 
causes that could have been related to chemotherapy. 
A 38  years-old woman with angiosarcoma arising from 
Table 1 Baseline characteristics (n = 21)
ECOG Eastern Cooperative Oncology Group, FNCLCC Fédération Nationale des 
Centres de Lutte Contre le Cancer
No. of patients Percentage
Age, years
 Median (range) 53 (24–76)
Gender
 Male 15 71
 Female 6 29
ECOG performance status
 0 4 19
 1 16 76
 2 1 5
Primary site
 Scalp 6 29
 Non‑scalp
  Visceral organs (e.g., liver) 7 33
  Heart 5 24
  Skin 2 10
  Breast 1 5
FNCLCC grade
 1 1 5
 2 7 33
 3 9 43
 Unknown 4 19
Initial stage at diagnosis
 III 11 52
 IV 10 48
Laboratory (mean, SD)
 Hemoglobin, g/dL 12.6 (2.0)
 Corrected calcium, mg/dL 9.3 (0.7)
 Lactate dehydrogenase, U/L 372 (243)
Number of metastatic site(s)
 Median (range) 2 (1–4)
Sites of metastases
 Lung 12 57
 Lymph nodes 9 43
 Bone 5 24
 Spleen 3 14
 Liver 1 5
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pericardium died due to pulmonary thromboembolism 
occurred in the midst of second cycle, with no clinical 
evidence of progression.
Objective responses to weekly paclitaxel were noted in 
11 patients (RR 52 %, 95 % CI 32–74 %), including four 
complete responses. Stable disease was observed in 6 
patients (29 %), leading to a disease control rate of 81 %. 
In order to explore predictive factors for clinical response 
to chemotherapy, we performed a logistic regression 
analysis with known clinical and laboratory parameters. 
However, RR was not significantly influenced by age, gen-
der, performance status, FNCLCC grade, number and 
site of metastases, or baseline laboratory parameters. We 
also tested whether the development of clinical responses 
was modified by interaction between the effects of 
parameters; the first-level interaction term between these 
variables was entered into separate multivariate model 
but we found no interaction between them.
Of the 21 patients analyzed in the study, the median 
PFS and OS were 5.7 months (95 % CI 5.1–6.3 months) 
and 18.6 months (95 % CI 9.9–27.3 months), respectively. 
The Kaplan–Meier estimates of PFS and OS are illus-
trated in Fig. 1. Again, in the Cox regression model, the 
estimated PFS or OS was not significantly influenced by 
any of the baseline parameters. After first-line failure, 
38 % of the patients received second-line therapy, mostly 
with pazopanib (n  =  7) and doxorubicin (n  =  1). For 
exploratory purposes, we compared OS between patients 
who received salvage therapy after first-line paclitaxel 
failure and who did not. Although statistically insignifi-
cant, those who received second-line therapy lived longer 
(21.2 versus 13.3 months, P = 0.105).
Discussion
In this retrospective study on a limited number of 
patients, we found that first-line therapy with weekly 
paclitaxel in Korean patients with metastatic angiosar-
coma can be both well tolerated and active, regardless 
of performance status or other baseline characteristics. 
First-line weekly paclitaxel achieved objective response 
and stable disease in 52 and 29 % of patients, respectively. 
The estimated median PFS and OS were 5.7  months 
(95  % CI 5.1–4.3) and 18.6  months (95  % CI 9.9–27.3), 
respectively. Although this study is retrospective in 
nature, the results provide evidence that Korean patients 
with metastatic angiosarcoma may derive benefit from 
weekly paclitaxel. The results are compared well with the 
outcomes obtained from previous retrospective studies 
[6, 8–10], as well as the prospective phase II ANGIOTAX 
study [12].
While the mode of action of paclitaxel in patients with 
metastatic angiosarcoma remains unclear [12], and dox-
orubicin-based chemotherapy remains the treatment of 
choice in metastatic STS [14], weekly paclitaxel seems to 
be an active and safe chemotherapy regimen in patients 
with chemotherapy-naïve, metastatic angiosarcoma. 
Unfortunately, ANGIOTAX-PLUS [15], a randomized 
phase II study testing paclitaxel with or without bevaci-
zumab, reported that the 6-month PFS rate was 56.7  % 
with weekly paclitaxel and 57.6 % with weekly paclitaxel 
plus bevacizumab. Although there are newer agents that 
can be used to treat metastatic STS, it is our conclusion 
that weekly paclitaxel should be offered in a first-line 
setting for patients with metastatic angiosarcoma. Pacli-
taxel can be administered to patients whose tumors have 
progressed after other agents such as doxorubicin. We 
believe this approach is not optimal because the patient’s 
performance status is likely to decline with each succes-
sive systemic treatment, and thus the opportunity to use 
paclitaxel can be lost.
Therefore, the identification of prognostic or predictive 
factors allowing the selection of patients who are likely to 
benefit from weekly paclitaxel is an important challenge. 
Table 2 Maximum grade toxicities per patient
All grades, N (%) Grades 3 or 4, N (%)
Anemia 5 (24 %) 2 (10 %)
Neutropenia 3 (14 %) 2 (10 %)
Thrombocytopenia 1 (5 %) 0
Infection 1 (5 %) 1 (5 %)
Nausea and vomiting 13 (62 %) 1 (5 %)
Anorexia 10 (48 %)
Stomatitis 6 (29 %) 0
Diarrhea 4 (19 %) 0
Fatigue 10 (48 %) 0
Peripheral neuropathy 14 (67 %) 0
Allergic reaction 2 (10 %) 0













Fig. 1 Kaplan–Meier curves for progression‑free survival (dotted line) 
and overall survival (solid line)
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Our study showed that, among 21 patients with meta-
static angiosarcoma, 4 (19  %) patients experienced 
progressive disease as their best response to weekly 
paclitaxel, which is comparable to findings in published 
reports. Although this study is retrospective in nature, 
it is clear that weekly paclitaxel may not be beneficial 
for all angiosarcoma patients with metastatic disease. 
In a large retrospective analysis [14], high tumor grade 
was an adverse prognostic factor for PFS and OS. We 
found that response to weekly paclitaxel was not related 
to the FNCLCC tumor grade or the performance status 
of patients. Besides clinical and laboratory parameters, 
appropriate patient selection based on molecular charac-
terization of tumor is one of the most extensively stud-
ied area in clinical research. While it is still at an early 
stage and it would take years before we see clinical appli-
cations, extensive work is ongoing to identify possible 
molecular markers, particularly in the angiogenesis path-
way. In patients with pretreated STS, pazopanib should 
be considered a treatment of choice based on a prospec-
tive phase III trial [7].
In the present study, 38  % of the patients received 
second-line therapy after the first-line paclitaxel fail-
ure. Considering the aggressive nature of the disease, 
it seems clear that only a small percentage of patients 
continue to have good performance status after first-
line therapy and are still medically fit to be offered 
salvage therapy. Nevertheless, we cannot exclude the 
possibility that the favorable outcomes seen in our 
patient population is related to the effect of further 
therapy. The strength of this study includes its single-
center nature with patients who were treated with 
weekly paclitaxel as first-line chemotherapy to avoid 
selection bias. It should be noted that our patient pop-
ulation was a consecutive series of patients taken from 
an academic, tertiary cancer center to reflect the real-
world experience with first-line weekly paclitaxel. That 
is, the study reflects real-world outcomes that may 
not necessarily be seen in randomized controlled tri-
als with selected patients. The limitations of this study 
include its retrospective nature, which may predis-
pose the study to selection bias and issues with miss-
ing data. Selection bias can be minimized by obtaining 
consecutive series of patients, as seen in the current 
results. The lack of central radiology review, variable 
modalities of imaging, and intervals between scans are 
potential weaknesses; however, we believe this better 
reflects the real-world experience of oncologists using 
first-line chemotherapy. Finally, the lack of comparative 
arm precludes our ability to determine whether weekly 
paclitaxel is superior, or at least as equivalent, to other 
agents including doxorubicin.
Conclusion
In present retrospective study, we reviewed the efficacy 
and tolerability of first-line chemotherapy with weekly 
paclitaxel in unselected Korean metastatic angiosarcoma 
patients. We found weekly paclitaxel chemotherapy is 
effective in controlling metastatic angiosarcoma. It is 
encouraging that the response rate and PFS for Korean 
patients were similar to those demonstrated in prior 
Western reports.
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